[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100569658":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":24,"centralContacts":28,"locations":34,"responsibleParty":44,"collaborators":24,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":24,"eligibilityCriteria":53,"healthyVolunteers":50,"sex":54,"minAge":55,"maxAge":24,"enrollmentInfo":56,"targetDuration":24,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":24,"overallStatus":36,"whyStopped":24,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"New Valley University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Nonsteroidal anti-inflammatory drugs","EXPERIMENTAL","Patients will undergo direct vision internal urethrotomy (DVIU) plus nonsteroidal anti-inflammatory drugs (NSAID) for 3 weeks.",[13],"Drug: Nonsteroidal anti-inflammatory drugs",{"label":15,"type":16,"description":17,"interventionNames":18},"Control group","PLACEBO_COMPARATOR","Patients will undergo direct vision internal urethrotomy (DVIU) plus a placebo for 3 weeks.",[19],"Drug: Placebo",[21,25],{"type":22,"name":9,"description":11,"armGroupLabels":23,"otherNames":24},"DRUG",[9],null,{"type":22,"name":26,"description":17,"armGroupLabels":27,"otherNames":24},"Placebo",[15],[29],{"name":30,"role":31,"phone":32,"phoneExt":24,"email":33},"Waheed F Abdelrasol, MD","CONTACT","00201207722518","waheed_fawzy@med.nvu.edu.eg",[35],{"facility":5,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":24,"geoPoint":24,"contacts":42},"RECRUITING","New Valley","New Valley Governorate","72511","Egypt","EG",[43],{"name":30,"role":31,"phone":32,"phoneExt":24,"email":33},{"type":45,"investigatorFullName":46,"investigatorTitle":47,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"PRINCIPAL_INVESTIGATOR","Waheed Fawzy Abdelrasol","Lecturer of Urology, Faculty of medicine, New Vally University, New Vally, Egypt","100569658","can-cox-2-inhibitor-decrease-stricture-recurrence-after-direct-vision-internal-urethrotomy-100569658",false,"NCT06697106","Can COX-2 Inhibitor Decrease Stricture Recurrence After Direct Vision Internal Urethrotomy?","Inclusion Criteria:\n\n* Age ≥ 18 years\n* American Society of Anesthesiologists (ASA) score ≤3.\n* Urethral stricture length ≤ 1.5 cm\n\nExclusion Criteria:\n\n* Recurrent urethral stricture ≥ 2 times.\n* Pelvic fracture urethral distraction defect (PFUDD).","MALE","18 Years",{"count":57,"type":58},82,"ESTIMATED","INTERVENTIONAL",[61],"NA","To evaluate the efficacy and safety of nonsteroidal anti-inflammatory drugs (NSAIDs) in preventing urethral stricture recurrence after direct visual internal urethrotomy.",[64,65,66,67],"COX-2 Inhibitor","Meloxicam","Stricture Recurrence","Direct Vision Internal Urethrotomy","2024-11-20",{"date":70,"type":71},"2024-11-21","ACTUAL",{"date":68,"type":71},{"date":74,"type":58},"2025-04-01",{"name":5,"class":6},1]